Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia.
Department of Obstetrics and Gynecology, Paracelsus Medical University, Salzburg, Austria.
Ultrasound Obstet Gynecol. 2020 Dec;56(6):879-884. doi: 10.1002/uog.22070. Epub 2020 Nov 9.
Pre-eclampsia (PE) is a significant contributor to adverse maternal and perinatal outcome; however, accurate prediction and early diagnosis of this condition remain a challenge. The aim of this study was to compare serum levels of growth-differentiation factor-15 (GDF-15) at three different gestational ages between asymptomatic women who subsequently developed preterm or term PE and healthy controls.
This was a case-control study drawn from a prospective observational study on adverse pregnancy outcomes in women attending for their routine second- and third-trimester hospital visits. Serum GDF-15 was determined in 300 samples using a commercial GDF-15 enzyme-linked immunosorbent assay: 120 samples at 19-24 weeks of gestation, 120 samples at 30-34 weeks and 60 samples at 35-37 weeks. Multiple linear regression was applied to logarithmically transformed GDF-15 control values to evaluate the influence of gestational age at blood sampling and maternal characteristics on GDF-15 results. GDF-15 multiples of the normal median (MoM) values, adjusted for gestational age and maternal characteristics, were compared between pregnancies that subsequently developed preterm or term PE and healthy controls.
Values of GDF-15 increased with gestational age. There were no significant differences in GDF-15 MoM values between cases of preterm or term PE and normotensive pregnancies at 19-24 or 35-37 weeks of gestation. At 30-34 weeks, GDF-15 MoM values were significantly increased in cases of preterm PE, but not in those who later developed term PE. Elevated GDF-15 MoM values were associated significantly with a shorter interval between sampling at 30-34 weeks and delivery with PE (P = 0.005).
Serum GDF-15 levels at 19-24 or 35-37 weeks of gestation are not predictive of preterm or term PE. At 30-34 weeks, GDF-15 levels are higher in women who subsequently develop preterm PE; however, this difference is small and GDF-15 is unlikely to be useful in clinical practice when used in isolation. Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd.
子痫前期(PE)是导致母婴不良围生结局的重要原因;然而,准确预测和早期诊断这一疾病仍然是一个挑战。本研究旨在比较在无症状孕妇中,血清生长分化因子 15(GDF-15)在三个不同的妊娠龄段的水平,这些孕妇随后发生早产或足月 PE 及健康对照组。
这是一项病例对照研究,来源于前瞻性观察研究妊娠不良结局的妇女在她们的常规第二和第三孕期医院就诊。使用商业 GDF-15 酶联免疫吸附试验检测 300 个样本的血清 GDF-15:120 个样本在 19-24 周,120 个样本在 30-34 周,60 个样本在 35-37 周。对数转换 GDF-15 对照值应用多元线性回归来评估采血时的孕龄和母亲特征对 GDF-15 结果的影响。校正孕龄和母亲特征后,比较随后发生早产或足月 PE 及健康对照组的 GDF-15 倍数中位数(MoM)值。
GDF-15 值随孕龄增加而增加。在 19-24 周或 35-37 周,早产或足月 PE 病例与正常血压妊娠的 GDF-15 MoM 值无显著差异。在 30-34 周时,早产 PE 病例的 GDF-15 MoM 值显著升高,但足月 PE 病例的 GDF-15 MoM 值没有升高。GDF-15 MoM 值升高与在 30-34 周采血与 PE 分娩之间的间隔时间较短显著相关(P=0.005)。
19-24 周或 35-37 周的血清 GDF-15 水平不能预测早产或足月 PE。在 30-34 周时,随后发生早产 PE 的妇女的 GDF-15 水平较高;然而,这种差异较小,当单独使用时,GDF-15 不太可能在临床上有用。版权所有©2020 ISUOG。由 John Wiley & Sons Ltd 出版。